Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Mac Researchers Find "surprising Link" Leads Towards A New Antibiotic
As the best drugs become increasingly resistant to superbugs, McMaster University researchers have discovered a completely different way of looking for a new antibiotic.
generic viagra online
Cobalis Corporation Is Awarded Two New International Patents In Canada And Mexico For Its Revolutionary Anti-Allergy Relief Product PreHistin(R)
Cobalis Corporation (OTC:CLSC) was recently awarded two additional International Patents in Canada and Mexico and has a patent pending application in Japan. PreHistin® is patented, safe for long-term daily use and available without a prescription. It is available in a cherry flavored, all natural, proprietary cyanocobalamin (vitamin B12) sub-lingual lozenge that is taken twice daily to regulate allergy sufferers" response to both indoor and outdoor allergens with daily and year round usage.
News of the day
University Of Antwerp Tests Vaccine For Mexican Flu - Vaccine Probably Available In November
In August and September, the University of Antwerp organises vaccine studies for different producers of Mexican flu (H1N1v) test vaccines. 300 to 400 volunteers will be recruited for these tests. "There is a good chance that a Mexican flu vaccine is available early November", expects vaccine expert prof. dr. Pierre van Damme, director of the Centre for the Evaluation of Vaccination (CEV), a department of the Vaccine & Infectious Disease Institute (VAXINFECTIO) at the University of Antwerp.
Cardiovascular

Diabetes Drug Shows MS Potential

A small trial testing the benefits in multiple sclerosis (MS) of a drug used to treat type II diabetes, in combination with beta-interferon-1a, has been shown to potentially prevent brain cell loss. The results of the trial in 21 people investigating the effects of pioglitazone (also known as Actos) were published last month in the Journal of Neuroimmunology. Although the results of the trial showed some evidence of less damage in the brains of people with MS, there were too few people in the study to determine whether this effect was real. Dr. Susan Kohlhaas, Research Communications Officer at the MS Society said, "These results suggest that pioglitazone may have some benefit in combination with beta-interferon for people with relapsing remitting MS, but this trial is not large enough to determine exactly what that benefit will be. She added, "A larger clinical trial is needed to decide whether or not pioglitazone will be of benefit to people with MS." Multiple Sclerosis Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009